¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÄö½Ì ¼­ºñ½º ½ÃÀå : ±â¼úº°, ½ÇÇè½Ç À¯Çüº°, ¿¬±¸ À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2024-2031³â)

Microbiome Sequencing Services Market Valuation - 2024-2031

The growing need for personalized medicine, advancements in sequencing technologies, and a greater comprehension of the microbiome's role in human health and disease are driving the market for microbiome sequencing services. According to the analyst from Verified Market Research, the Microbiome Sequencing Services Market is estimated to reach a valuation of USD 4 Billion over the forecast period 2031, subjugating around USD 1.63 Billion valued in 2023.

A growing understanding of the role of the microbiome in disease prevention, diagnosis, and treatment and the growth of academic-biotech partnerships, are further factors driving the market. It enables the market to grow at a CAGR of 11.87% from 2024 to 2031.

Microbiome Sequencing Services Market: Definition/Overview

Microbiome sequencing services are the process of detecting and analyzing the genetic material of microorganisms found in a specific environment, such as the human body or soil, using high-throughput sequencing technologies. This service gives precise insights into the structure and function of microbial communities, allowing for a better understanding of their roles in health and illness.

Furthermore, microbiome sequencing has a wide range of applications, including healthcare, where it is used to examine the impact of the microbiome on disorders such as inflammatory bowel disease, obesity, and diabetes, ultimately leading to personalized medication. It also plays an important role in agricultural research, analyzing soil microbiomes to increase crop productivity, and in environmental science, assessing microbial diversity and function in various ecosystems.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Advancements in High-throughput Sequencing Technologies Influence the growth of the Microbiome Sequencing Services Market?

Rapid improvements in high-throughput sequencing technologies, including Next-Generation Sequencing (NGS), have reduced the cost of microbial genome sequencing while increasing its speed and accuracy. This technical advancement has made microbiome sequencing more accessible and possible for a variety of academic and therapeutic applications, resulting in increased demand for these services.

Microbiome sequencing has applications beyond human health, such as agriculture, environmental science, and pharmaceuticals. In healthcare, microbiome sequencing is used to produce personalized medicine, improve diagnostic methods, and create novel therapeutic tactics. In agriculture, it aids in improving soil health, crop output, and understanding plant-microbe interactions. This growing number of applications in many sectors has fueled the expansion of the Microbiome Sequencing Services Market.

Furthermore, there is a rising interest in examining the human microbiome and its role in health and disease. Research in this field has helped us understand the function of the microbiome in a variety of disorders, including obesity, diabetes, autoimmune diseases, and even mental health difficulties. This increased emphasis on microbiome research has resulted in a surge in demand for sequencing services to precisely analyze microbial communities.

How will Need for Highly Skilled Professionals Favor Microbiome Sequencing Services Market?

The complexity of analyzing and interpreting the enormous volumes of data generated is one of the major obstacles to the Microbiome Sequencing Services Market. Data analysis is especially difficult due to the diversity of microbial populations and their interactions in various settings or hosts. This complexity demands sophisticated bioinformatics tools and experience, which creates an obstacle for researchers and enterprises without in-house capabilities or access to modern analytical platforms, limiting the market's expansion.

Microbiome research lacks standardized procedures for sample collection, DNA extraction, sequencing protocols, and data processing. This unpredictability makes it difficult to reproduce and compare results across studies and providers. The lack of globally acknowledged standards and methodologies makes it challenging to evaluate and compare findings, proving crucial for furthering research and developing microbiome-based applications and inhibiting commercial adoption.

Category-wise Acumens

How Does the Dominance of the Sequencing by Synthesis (SBS) Technology Impact the Market?

According to VMR analyst, the sequencing by synthesis (SBS) segment is expected to dominate the segment within the Microbiome Sequencing Services Market. SBS technology, as represented by Next-Generation Sequencing (NGS) platforms such as Illumina's sequencing systems, has high-throughput capabilities, allowing for the simultaneous sequencing of millions of DNA molecules. This efficiency is critical for microbiome sequencing, which involves analyzing complex and diverse microbial communities. This capacity to process huge volumes of samples rapidly and efficiently is a key reason for SBS's dominant position in the market.

SBS technology ensures excellent precision and reliability in sequencing findings. It has a lower error rate than other sequencing technologies, which is important when identifying and measuring microbial species in a community. The great quality of SBS technology allows researchers and physicians to make educated judgements based on accurate and dependable data, contributing to its widespread adoption.

Furthermore, although the initial investment in SBS technology can be large, the per-sample cost of sequencing has dramatically lowered over the years as SBS technology has advanced and the market has become more competitive. This cost reduction has made SBS more accessible to a wider group of researchers and institutions, allowing for more comprehensive and diverse microbiome research programmes. SBS's low cost, combined with its high throughput and accuracy, make it an appealing choice for microbiome sequencing services.

How Does Access to Advanced Technologies Contribute to the Dominance of Outsourced Segment?

The outsourced segment is estimated to hold the largest share of the Microbiome Sequencing Services Market during the forecast period. Outsourcing microbiome sequencing enables research organizations and businesses to leverage cutting-edge sequencing technologies and bioinformatics tools without incurring significant equipment and training costs. Service providers specialize in sequencing and have the experience and infrastructure to manage complicated projects, which can dramatically enhance sequencing quality and speed. This access is especially useful for small and medium-sized businesses and academic institutions that may lack the means to operate cutting-edge sequencing facilities in-house.

Furthermore, outsourced microbiome sequencing services provide greater flexibility and scalability than internal capabilities. Service providers can readily scale their operations up or down to meet the demands and specific needs of their clients, accommodating everything from tiny exploratory investigations to large-scale sequencing initiatives. This scalability enables research organizations to respond swiftly to changing project scopes and research goals, rather than being constrained by the capacity of their internal facilities.

Country/Region-wise Acumens

How will Demand for Microbiome Sequencing Services in North America Influence the Market?

According to VMR Analysis, the North American region is estimated to dominate in Microbiome Sequencing Services Market during the forecast period. North America is at the forefront of implementing advanced technology, such as next-generation sequencing (NGS), which is essential for microbiome sequencing. The region's openness to incorporate new technology into research and clinical practices improves its ability to perform large-scale microbiome studies, increasing in demand for sequencing services. The existence of leading sequencing technology businesses and startups in North America reinforces this trend.

Furthermore, in North America, there is a rising recognition of the microbiome's significance in health, illness, and environmental applications. This understanding is evident in the increased use of microbiome sequencing in a variety of disciplines, including healthcare, pharmaceuticals, agriculture, and environmental science. For example, in healthcare, there is a considerable emphasis on creating microbiome-based diagnostics, treatments, and personalized medicine. This broad application scope promotes demand for microbiome sequencing services, supporting regional market growth.

Will the Asia Pacific Propel the Demand for Microbiome Sequencing Services?

Asia Pacific is expected to grow at the highest CAGR in the Microbiome Sequencing Services Market during the forecast period. Countries in the Asia Pacific region, particularly China, Japan, South Korea, and Australia, are investing heavily in biotechnology R&D. This includes funding for the development of research infrastructure, including cutting-edge laboratories and sequencing facilities, as well as support for biotech firms and academic microbiome research programs. These investments are laying a solid platform for microbiome research and sequencing services, hence boosting market expansion.

Furthermore, the importance of the microbiome in human health, nutrition, and illness is becoming more widely recognized in Asia Pacific. This increased awareness is generating interest and research in fields such as probiotics, personalized medicine, and microbiome-based therapeutics. The rising prevalence of chronic diseases in the region, which may be connected to microbial imbalances is driving research activities and demand for sequencing services to better understand and treat these conditions.

Competitive Landscape

The competitive landscape of the Microbiome Sequencing Services Market is marked by fierce competition among firms seeking to develop and broaden their offerings. Partnerships, collaborations, and acquisitions are also frequent tactics used by businesses to boost their market position, broaden their geographic reach, and improve their service offering.

Some of the prominent players operating in the Microbiome Sequencing Services Market include:

Charles River Laboratories, Eurofins Scientific, BGI, CosmosID, Microba, QIAGEN, Microbiome Insights, BaseClear, CD Genomics, Zymo Research, OraSure Technologies, MR DNA, Eremid Genomic Services, Clinical-Microbiomics A/S, Novogene Co., EzBiome, Boster Biological Technology, Zifo, Macrogen.

Latest Developments:

In May 2023, CosmosID presented new findings on the gut microbiome and its relationship with chronic inflammatory disorders at the American Gastroenterological Association (AGA) meeting.

In February 2023, Charles River Laboratories announced a collaboration with Danone Nutricia Research to create a microbiome research centre focusing on early-life nutrition and gut health.

In January 2024, Eurofins Scientific acquired LabWest, an Australian contract research organization (CRO), boosting its service offerings in Asia-Pacific, including microbiome testing.

In December 2023, BGI announced its new metagenomics sequencing tool, MGseq-1000, which provides researchers with a faster and more cost-effective choice for microbiome investigation.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MICROBIOME SEQUENCING SERVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, BY END USER

• 5.1 Overview
• 5.2 Pharmaceutical and Biotechnology Companies
• 5.3 Academic & Research Institutes
• 5.4 Others

6 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Shotgun Sequencing
• 6.3 Targeted Gene Sequencing
• 6.4 RNA Sequencing
• 6.5 Whole Genome Sequencing
• 6.6 Others

7 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, BY TECHNOLOGY

• 7.1 Overview
• 7.2 Sequencing by Synthesis (SBS)
• 7.3 Sequencing by Ligation (SBL)
• 7.4 Pyrosequencing
• 7.5 Sanger Sequencing
• 7.6 Others

8 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, BY LABORATORY TYPE

• 8.1 Overview
• 8.2 Wet Labs
• 8.3 Dry Labs

9 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, BY RESEARCH TYPE

• 9.1 Overview
• 9.1 Outsourced
• 9.2 Internal

10 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET, BY GEOGRAPHY

• 10.1 Overview
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 U.K.
  • 10.3.3 France
  • 10.3.4 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Argentina
• 10.6 Rest of the World
  • 10.6.1. Latin America
  • 10.6.2. Middle East & Africa

11 GLOBAL MICROBIOME SEQUENCING SERVICES MARKET COMPETITIVE LANDSCAPE

• 11.1 Overview
• 11.2 Company Market Share
• 11.3 Vendor Landscape
• 11.4 Key Development Strategies

12 COMPANY PROFILES

• 12.1 Charles River Laboratories
  • 12.1.1 Overview
  • 12.1.2 Financial Performance
  • 12.1.3 Product Outlook
  • 12.1.4 Key Developments
• 12.2 Eurofins Scientific
  • 12.2.1 Overview
  • 12.2.2 Financial Performance
  • 12.2.3 Product Outlook
  • 12.2.4 Key Developments
• 12.3 BGI
  • 12.3.1 Overview
  • 12.3.2 Financial Performance
  • 12.3.3 Product Outlook
  • 12.3.4 Key Developments
• 12.4 CosmosID
  • 12.4.1 Overview
  • 12.4.2 Financial Performance
  • 12.4.3 Product Outlook
  • 12.4.4 Key Developments
• 12.5 Microba
  • 12.5.1 Overview
  • 12.5.2 Financial Performance
  • 12.5.3 Product Outlook
  • 12.5.4 Key Developments
• 12.6 QIAGEN
  • 12.6.1 Overview
  • 12.6.2 Financial Performance
  • 12.6.3 Product Outlook
  • 12.6.4 Key Developments
• 12.7 Microbiome Insights
  • 12.7.1 Overview
  • 12.7.2 Financial Performance
  • 12.7.3 Product Outlook
  • 12.7.4 Key Developments
• 12.8 BaseClear
  • 12.8.1 Overview
  • 12.8.2 Financial Performance
  • 12.8.3 Product Outlook
  • 12.8.4 Key Developments
• 12.9 CD Genomics
  • 12.9.1 Overview
  • 12.9.2 Financial Performance
  • 12.9.3 Product Outlook
  • 12.9.4 Key Developments
• 12.10 Zymo Research
  • 12.10.1 Overview
  • 12.10.2 Financial Performance
  • 12.10.3 Product Outlook
  • 12.10.4 Key Developments

13 KEY DEVELOPMENTS

• 13.1 Product Launches/Developments
• 13.2 Mergers and Acquisitions
• 13.3 Business Expansions
• 13.4 Partnerships and Collaborations

14 Appendix

• 14.1 Related Research